{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:17:25Z","timestamp":1792163845789,"version":"4.4.0"},"reference-count":79,"publisher":"EDITORA SCIENTIFIC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Bras. Psiquiatr."],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>INTRODU\u00c7\u00c3O: O transtorno de ansiedade social (TAS) \u00e9 o transtorno de ansiedade mais comum, freq\u00fcentemente sem remiss\u00f5es, sendo comumente associado com importante preju\u00edzo funcional e psicossocial. A Associa\u00e7\u00e3o M\u00e9dica Brasileira (AMB), atrav\u00e9s do \"Projeto Diretrizes\", busca desenvolver consensos de diagn\u00f3stico e tratamento para as doen\u00e7as mais comuns. O objetivo deste trabalho \u00e9 apresentar os achados mais relevantes das diretrizes relativas ao tratamento do TAS, servindo de refer\u00eancia para o m\u00e9dico generalista e especialista. M\u00c9TODO: O m\u00e9todo utilizado foi o proposto pela AMB. A busca foi realizada nas bases de dados do MEDLINE (PubMed), Scopus, Web of Science e Lilacs, entre 1980 e 2010. A estrat\u00e9gia utilizada baseou-se em perguntas estruturadas na forma P.I.C.O (acr\u00f4nimo das iniciais \"paciente ou popula\u00e7\u00e3o\"; \"interven\u00e7\u00e3o, indicador ou exposi\u00e7\u00e3o\"; \"controle ou compara\u00e7\u00e3o\" e; \"outcome ou desfecho\"). RESULTADOS: Estudos evidenciam que o tratamento farmacol\u00f3gico de primeira linha para adultos e crian\u00e7as s\u00e3o os inibidores seletivos de recapta\u00e7\u00e3o de serotonina e os inibidores de recapta\u00e7\u00e3o de serotonina e noradrenalina, enquanto que a terapia cognitivo-comportamental \u00e9 apontada como melhor tratamento psicoter\u00e1pico. Al\u00e9m disso, algumas comorbidades psiqui\u00e1tricas foram associadas a uma pior evolu\u00e7\u00e3o do TAS. CONCLUS\u00d5ES: Apesar da alta preval\u00eancia, o TAS acaba por n\u00e3o receber a devida aten\u00e7\u00e3o e tratamento. A melhor escolha para o tratamento de adultos \u00e9 a associa\u00e7\u00e3o psicoterapia cognitivo-comportamental com inibidores seletivos de recapta\u00e7\u00e3o de serotonina e os inibidores de recapta\u00e7\u00e3o de serotonina e noradrenalina. Outras op\u00e7\u00f5es como benzodiazep\u00ednicos ou inibidores da monoamino-oxidase devem ser usados como segunda e terceira op\u00e7\u00e3o respectivamente.<\/jats:p>","DOI":"10.1590\/s1516-44462011000300014","type":"journal-article","created":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T21:22:29Z","timestamp":1317331349000},"page":"292-302","source":"Crossref","is-referenced-by-count":10,"title":["Diretrizes da Associa\u00e7\u00e3o M\u00e9dica Brasileira para o tratamento do transtorno de ansiedade social"],"prefix":"10.47626","volume":"33","author":[{"given":"Michelle N.","family":"Levitan","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Brasil; Instituto Nacional de Ci\u00eancia e Tecnologia Translacional em Medicina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos H. N.","family":"Chagas","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil; Instituto Nacional de Ci\u00eancia e Tecnologia Translacional em Medicina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A. S.","family":"Crippa","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil; Instituto Nacional de Ci\u00eancia e Tecnologia Translacional em Medicina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele G.","family":"Manfro","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul, Brasil; Instituto Nacional de Psiquiatria do Desenvolvimento para a Inf\u00e2ncia e Adolesc\u00eancia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz A. B.","family":"Hetem","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia C.","family":"Andrada","sequence":"additional","affiliation":[{"name":"Associa\u00e7\u00e3o M\u00e9dica Brasileira"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni A.","family":"Salum","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul, Brasil; Instituto Nacional de Psiquiatria do Desenvolvimento para a Inf\u00e2ncia e Adolesc\u00eancia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Isolan","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C. F.","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brasil; Instituto Nacional de Ci\u00eancia e Tecnologia Translacional em Medicina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio E.","family":"Nardi","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Brasil; Instituto Nacional de Ci\u00eancia e Tecnologia Translacional em Medicina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27448","reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archpsyc.62.6.629","article-title":"Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication","volume":"62","author":"Wang PS","year":"2005","journal-title":"Arch Gen Psychiatry."},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archpsyc.1991.01810340070009","article-title":"Cognitive-behavioral and pharmacological treatments of social phobia: A controlled study","volume":"48","author":"Gelernter CS","year":"1991","journal-title":"Arch Gen Psychiatry."},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpsyc.61.10.1005","article-title":"Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia","volume":"61","author":"Davidson JR","year":"2004","journal-title":"Arch Gen Psychiatry."},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1017\/S0033291701004020","article-title":"Long-term outcome of social phobia treated by exposure","volume":"31","author":"Fava GA","year":"2001","journal-title":"Psychol Med","ISSN":"https:\/\/id.crossref.org\/issn\/0033-2917","issn-type":"print"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archgenpsychiatry.2010.11","article-title":"A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder","volume":"67","author":"Blanco C","year":"2010","journal-title":"Arch Gen Psychiatry."},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11920-003-0058-5","article-title":"Cognitive-behavioral treatment of social phobia: new advances","volume":"5","author":"Huppert JD","year":"2003","journal-title":"Curr Psychiatry Rep."},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1037\/0022-006X.74.3.568","article-title":"Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial","volume":"74","author":"Clark DM","year":"2006","journal-title":"J Consult Clin Psychol."},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0005-7967(97)00022-3","article-title":"A cognitive-behavioral model of anxiety in social phobia","volume":"35","author":"Rapee RM","year":"1997","journal-title":"Behav Res Ther."},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/08039480903426929","article-title":"Pre-treatment patient variables as predictors of drop-out and treatment outcome in cognitive behavioural therapy for social phobia: A systematic review","volume":"64","author":"Eskildsen A","year":"2010","journal-title":"Nord J Psychiatry."},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0005-7967(02)00176-6","article-title":"Cognitive therapy for social phobia: individual versus group treatment","volume":"41","author":"Stangier U","year":"2003","journal-title":"Behav Res Ther."},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0005-7967(93)90120-J","article-title":"Exposure with and without cognitive therapy for generalized social phobia: effects of individual and group treatment","volume":"31","author":"Scholing A","year":"1993","journal-title":"Behav Res Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0005-7967","issn-type":"print"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0005-7967(90)90001-Y","article-title":"Exposure in vivo vs social skills training for social phobia: long-term outcome and differential effects","volume":"28","author":"Wlazlo Z","year":"1990","journal-title":"Behav Res Ther."},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1037\/0022-006X.56.2.251","article-title":"Treatment of severe social phobia: effects of guided exposure with and without cognitive restructuring","volume":"56","author":"Mattick RP","year":"1988","journal-title":"J Consult Clin Psychol."},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archpsyc.55.12.1133","article-title":"Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome","volume":"55","author":"Heimberg RG","journal-title":"Arch Gen Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/15374410701817907","article-title":"Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents","volume":"37","author":"Silverman WK","year":"2008","journal-title":"J Clin Child Adolesc Psychol."},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/da.20410","article-title":"Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety","volume":"25","author":"Segool NK","year":"2008","journal-title":"Depress Anxiety."},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00005053-199510000-00006","article-title":"Cognitive-behavioral group treatment for social phobia in adolescents: A preliminary study","volume":"183","author":"Albano AM","year":"1995","journal-title":"J Nerv Ment Dis."},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/1469-7610.00659","article-title":"The treatment of childhood social phobia: the effectiveness of a social skills training-based, cognitive-behavioural intervention, with and without parental involvement","volume":"41","author":"Spence SH","year":"2000","journal-title":"J Child Psychol Psychiatry."},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0887-6185(03)00027-6","article-title":"A brief group cognitive-behavioral intervention for social phobia in childhood","volume":"18","author":"Gallagher HM","year":"2004","journal-title":"J Anxiety Disord."},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1037\/0022-006X.67.5.675","article-title":"Contingency management, self-control, and education support in the treatment of childhood phobic disorders: a randomized clinical trial","volume":"67","author":"Silverman WK","year":"1999","journal-title":"J Consult Clin Psychol."},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/14737175.8.2.235","article-title":"Pharmacotherapy for social anxiety disorder: a systematic review","volume":"8","author":"Ipser JC","year":"2008","journal-title":"Expert Rev Neurother."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0165-0327(98)00090-1","article-title":"The role of drug therapy in social phobia","volume":"50","author":"Lydiard RB","year":"1998","journal-title":"J Affect Disord."},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004714-199804000-00005","article-title":"Imipramine in the treatment of social phobia","volume":"18","author":"Simpson HB","year":"1998","journal-title":"J Clin Psychopharmacol."},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-198808000-00008","article-title":"Tranylcypromine in social phobia","volume":"8","author":"Versiani M","year":"1988","journal-title":"J Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1037\/0022-006X.71.6.1058","article-title":"Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial","volume":"71","author":"Clark DM","year":"2003","journal-title":"J Consult Clin Psychol."},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","article-title":"Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study","volume":"22","author":"Kobak KA","year":"2002","journal-title":"J Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biopsych.2005.03.029","article-title":"Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo","volume":"58","author":"Furmark T","year":"2005","journal-title":"Biol Psychiatry."},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","article-title":"Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study","volume":"64","author":"Liebowitz MR","year":"2003","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","article-title":"Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study","volume":"158","author":"Van Ameringen MA","year":"2001","journal-title":"Am J Psychiatry."},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","article-title":"Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study","volume":"19","author":"Lader M","year":"2004","journal-title":"Depress Anxiety."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","article-title":"Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study","volume":"186","author":"Kasper S","year":"2005","journal-title":"Br J Psychiatry."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phobia\/social anxiety disorder: Randomised, double-blind, placebo-controlled study. Paroxetine Study Group","volume":"175","author":"Baldwin D","year":"1999","journal-title":"Br J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1250","issn-type":"print"},{"issue":"8","key":"ref33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial","volume":"280","author":"Stein MB","year":"1998","journal-title":"JAMA."},{"issue":"4","key":"ref34","first-page":"402","article-title":"A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa","volume":"89","author":"Stein DJ","year":"1999","journal-title":"S Afr Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0038-2469","issn-type":"print"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0447.1999.tb10845.x","article-title":"Paroxetine in social anxiety disorder: a randomized placebo-controlled study","volume":"100","author":"Allgulander C","year":"1999","journal-title":"Acta Psychiatr Scand."},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","article-title":"Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study","volume":"156","author":"Stein MB","year":"1999","journal-title":"Am J Psychiatry."},{"issue":"1-2","key":"ref37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","article-title":"Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine","volume":"115","author":"van Vliet IM","year":"1994","journal-title":"Psychopharmacology (Berl)","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S1461145706006602","article-title":"Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study","volume":"10","author":"Asakura S","year":"2007","journal-title":"Int J Neuropsychopharmacol."},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","article-title":"Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial","volume":"177","author":"Stein MB","year":"2005","journal-title":"Psychopharmacology (Berl)","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.jcp.0000138764.31106.60","article-title":"A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder","volume":"24","author":"Rickels K","year":"2004","journal-title":"J Clin Psychopharmacol."},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","article-title":"A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder","volume":"66","author":"Liebowitz MR","year":"2005","journal-title":"J Clin Psychiatry."},{"issue":"6","key":"ref42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","article-title":"Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine","volume":"19","author":"Allgulander C","year":"2004","journal-title":"Hum Psychopharmacol."},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/da.10112","article-title":"Citalopram treatment of social anxiety disorder with comorbid major depression","volume":"17","author":"Schneier FR","year":"2003","journal-title":"Depress Anxiety."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.161.3.353","article-title":"Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine","volume":"161","author":"Versiani M","year":"1992","journal-title":"Br J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1250","issn-type":"print"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/da.10096","article-title":"Pharmacological treatment of social anxiety disorder: a meta-analysis","volume":"18","author":"Blanco C","year":"2003","journal-title":"Depress Anxiety."},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","article-title":"Treatment of social phobia with clonazepam and placebo","volume":"13","author":"Davidson JR","year":"1993","journal-title":"J Clin Psychopharmacol."},{"key":"ref47","first-page":"167","article-title":"Double-blind placebo controlled trial with bromazepam in social phobia","volume":"46","author":"Versiani M","year":"1997","journal-title":"J Bras Psiquiatr."},{"issue":"4","key":"ref48","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/0002-8703(84)90599-4","article-title":"Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo","volume":"108","author":"James I","year":"1984","journal-title":"Am Heart J."},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archpsyc.61.11.1153","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder","volume":"61","author":"Wagner KD","year":"2004","journal-title":"Arch Gen Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"4","key":"ref50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.CHI.0000037049.04952.9F","article-title":"Fluoxetine for the treatment of childhood anxiety disorders","volume":"42","author":"Birmaher B","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"5","key":"ref51","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00004583-200105000-00016","article-title":"Sertraline in children and adolescents with social anxiety disorder: an open trial","volume":"40","author":"Compton SN","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"6","key":"ref52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/cap.2007.0007","article-title":"An open-label trial of scitalopram in children and adolescents with social anxiety disorder","volume":"17","author":"Isolan L","year":"2007","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"10","key":"ref53","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.v66n1009","article-title":"A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder","volume":"66","author":"Montgomery SA","year":"2005","journal-title":"J Clin Psychiatry."},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archpsyc.59.12.1111","article-title":"Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study","volume":"59","author":"Stein DJ","year":"2002","journal-title":"Arch Gen Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0005-7894(05)80095-4","article-title":"Social phobia subtype and avoidant personality disorder: Effect on severity of social phobia, impairment, and outcome of cognitive behavioral treatment","volume":"26","author":"Brown EJ","year":"1995","journal-title":"Behav Ther."},{"issue":"10","key":"ref56","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0005-7967(96)00028-9","article-title":"Clinical features affecting treatment outcome in social phobia","volume":"34","author":"Turner SM","year":"1996","journal-title":"Behav Res Ther."},{"issue":"10","key":"ref57","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","article-title":"Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"Stein MB","year":"2001","journal-title":"Am J Psychiatry."},{"issue":"417","key":"ref58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1034\/j.1600-0447.108.s417.7.x","article-title":"Pharmacotherapy of social phobia","author":"Davidson JR","year":"2003","journal-title":"Acta Psychiatr Scand Suppl."},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1590\/S1516-44462005000100009","article-title":"Early-onset social anxiety disorder in adults: clinical and therapeutic features","volume":"27","author":"Menezes GB","year":"2005","journal-title":"Rev Bras Psiquiatr."},{"issue":"7","key":"ref60","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00004583-199507000-00007","article-title":"Psychiatric characteristics of children with selective mutism: a pilot study","volume":"34","author":"Black B","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"8","key":"ref61","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/00004583-200208000-00012","article-title":"Prevalence and description of selective mutism in a school-based sample","volume":"41","author":"Bergman RL","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"5","key":"ref62","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00004583-199605000-00015","article-title":"Elective mutism: an analysis of 100 cases","volume":"35","author":"Steinhausen HC","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"3","key":"ref63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1037\/h0088982","article-title":"Selective mutism: Phenomenological characteristics","volume":"13","author":"Ford MA","year":"1998","journal-title":"Sch Psychol."},{"issue":"1","key":"ref64","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s007870050041","article-title":"Selective mutism among second-graders in elementary school","volume":"7","author":"Kumpulainen K","year":"1998","journal-title":"Eur Child Adolesc Psychiatry."},{"issue":"5","key":"ref65","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00004583-199605000-00016","article-title":"Fluoxetine treatment of children with selective mutism: an open trial","volume":"35","author":"Dummit ES, 3rd","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0890-8567","issn-type":"print"},{"issue":"10","key":"ref66","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1177\/070674370805301010","article-title":"Comparing interventions for selective mutism: a pilot study","volume":"53","author":"Manassis K","year":"2008","journal-title":"Can J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0706-7437","issn-type":"print"},{"issue":"4","key":"ref67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jbtep.2007.12.002","article-title":"Group therapy for selective mutism - a parents' and children's treatment group","volume":"39","author":"Sharkey L","year":"2008","journal-title":"J Behav Ther Exp Psychiatry."},{"issue":"4","key":"ref68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/da.20121","article-title":"Impact of depressive symptoms on the treatment of generalized social anxiety disorder","volume":"22","author":"Ledley DR","year":"2005","journal-title":"Depress Anxiety."},{"issue":"3","key":"ref69","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/da.20390","article-title":"Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy","volume":"26","author":"Marom S","year":"2009","journal-title":"Depress Anxiety."},{"issue":"1","key":"ref70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0005-7967(00)00114-5","article-title":"Comorbid anxiety and mood disorders among persons with social anxiety disorder","volume":"40","author":"Erwin BA","year":"2002","journal-title":"Behav Res Ther."},{"issue":"1-3","key":"ref71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jad.2008.08.008","article-title":"Cognitive therapy for depressed adults with comorbid social phobia","volume":"114","author":"Smits JA","year":"2009","journal-title":"J Affect Disord."},{"issue":"4","key":"ref72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jpsychires.2008.04.012","article-title":"Understanding social anxiety as a risk for alcohol use disorders: fear of scrutiny, not social interaction fears, prospectively predicts alcohol use disorders","volume":"43","author":"Buckner JD","year":"2009","journal-title":"J Psychiatr Res."},{"issue":"1","key":"ref73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.janxdis.2008.03.013","article-title":"Self-medication of anxiety disorders with alcohol and drugs: Results from a nationally representative sample","volume":"23","author":"Robinson J","year":"2009","journal-title":"J Anxiety Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6185","issn-type":"print"},{"issue":"12","key":"ref74","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/da.20442","article-title":"Implications of comorbid alcohol dependence among individuals with social anxiety disorder","volume":"25","author":"Buckner JD","year":"2008","journal-title":"Depress Anxiety."},{"issue":"4","key":"ref75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0887-6185(00)00026-8","article-title":"Comorbid generalized anxiety disorder in primary social phobia: symptom severity, functional impairment, and treatment response","volume":"14","author":"Mennin DS","year":"2000","journal-title":"J Anxiety Disord."},{"issue":"7","key":"ref76","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00004583-200107000-00013","article-title":"Comorbidity in childhood anxiety disorders and treatment outcome","volume":"40","author":"Kendall PC","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"3","key":"ref77","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.psychres.2008.06.025","article-title":"Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder","volume":"175","author":"Nardi AE","year":"2010","journal-title":"Psychiatry Res."},{"issue":"4","key":"ref78","first-page":"444","article-title":"[Guidelines of the Brazilian Medical Association for the diagnosis and differential diagnosis of social anxiety disorder]","volume":"32","author":"Chagas MH","year":"2010","journal-title":"Rev Bras Psiquiatr."},{"issue":"8","key":"ref79","first-page":"9S","article-title":"Clinical practice guidelines: Management of anxiety disorders","volume":"51","year":"2006","journal-title":"Can J Psychiatry."}],"container-title":["Revista Brasileira de Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rbp\/v33n3\/14.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:51:18Z","timestamp":1686372678000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-44462011000300014&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1516-44462011000300014"],"URL":"https:\/\/doi.org\/10.1590\/s1516-44462011000300014","relation":{},"ISSN":["1516-4446"],"issn-type":[{"value":"1516-4446","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}